Chinese Vaccine Maker CanSino Expects to Turn Profit
MSN - 27 Mar 2025Chinese Vaccine Maker CanSino Expects to Turn Profit ...
cansino
Chinese Vaccine Maker CanSino Expects to Turn Profit ...
Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
simplywall.st - 26 Mar 2025Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet? ...
Chinese Vaccine Maker CanSino Expects to Turn Profit
Yahoo Finance - 27 Mar 2025Chinese Vaccine Maker CanSino Expects to Turn Profit ...
CanSino Biologics Releases 2024 Annual Results
TipRanks - 25 Mar 2025CanSino Biologics Releases 2024 Annual Results ...
Chandra Cansino To Be SSB New CEO
Channel 5 Belize - 01 Apr 2025Chandra Cansino To Be SSB New CEO ...
Chinese Vaccine Maker CanSino Expects to Turn Profit
MarketScreener - 27 Mar 2025Chinese Vaccine Maker CanSino Expects to Turn Profit ...
Chandra Nisbet Cansino tapped to lead Social Security Board
Belize News and Opinion on www.breakingbelizenews.com - 02 Apr 2025Chandra Nisbet Cansino tapped to lead Social Security Board ...
China's CanSino receives over $17 M from Bill & Melinda Gates Foundation to accelerate polio vaccine development
BioSpectrum Asia - 10 Oct 2024China's CanSino receives over $17 M from Bill & Melinda Gates Foundation to accelerate polio vaccine development ...
The CanSino Biologics Ad5-nCoV-S [recombinant] COVID-19 vaccine: What you need to know
World Health Organization (WHO) - 10 Jun 2022The CanSino Biologics Ad5-nCoV-S [recombinant] COVID-19 vaccine: What you need to know ...
CanSinoBIO to Showcase China's Vaccine Innovation at 2025 World Government Summit in Dubai
PR Newswire - 17 Feb 2025CanSinoBIO to Showcase China's Vaccine Innovation at 2025 World Government Summit in Dubai ...
CanSino Biologics to Announce 2024 Annual Results and Dividend Consideration
TipRanks - 12 Mar 2025CanSino Biologics to Announce 2024 Annual Results and Dividend Consideration ...
Nibm-cansino Biologics Moa Will Boost Vaccine Development, research Ecosystem - Chang
Bernama - 25 Jul 2024Nibm-cansino Biologics Moa Will Boost Vaccine Development, research Ecosystem - Chang ...
K.H.M.H. C.E.O. Chandra Cansino to Chair S.S.B.
Channel 5 Belize - 02 Apr 2025K.H.M.H. C.E.O. Chandra Cansino to Chair S.S.B. ...
FAST NEWS: CanSino’s quarterly revenue rises, but loss also widens
Bamboo Works - 30 Apr 2024FAST NEWS: CanSino’s quarterly revenue rises, but loss also widens ...
After AstraZeneca mRNA deal, CanSino eyes other production partnerships: Reuters
Fierce Pharma - 05 Sep 2023After AstraZeneca mRNA deal, CanSino eyes other production partnerships: Reuters ...
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet - 20 Jul 2020Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial ...
China's CanSino in mRNA vaccine deal with AstraZeneca
Reuters - 09 Aug 2023China's CanSino in mRNA vaccine deal with AstraZeneca ...
CanSino says vaccine demand down after China’s mass Covid infections
Financial Times - 14 Feb 2023CanSino says vaccine demand down after China’s mass Covid infections ...
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlle
The Lancet - 23 Dec 2021Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlle ...